NCT00602823View on ClinicalTrials.gov

Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva)

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2006

Study Completion Date

May 31, 2006

Conditions
Psoriasis
All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT00602823 - Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva) | Biotech Hunter | Biotech Hunter